MapLight Therapeutics, Inc. Common Stock Total Liabilities
MapLight Therapeutics, Inc. Common Stock total liabilities. Based on the latest financial reports, MapLight Therapeutics, Inc. Common Stock (MPLT) has total liabilities worth $20.05 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check MapLight Therapeutics, Inc. Common Stock liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of MapLight Therapeutics, Inc. Common Stock (2022–2025)
Total liabilities of MapLight Therapeutics, Inc. Common Stock from 2022 to 2025. This chart illustrates how MapLight Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of MapLight Therapeutics, Inc. Common Stock to see how much of total assets are deployed in long-term investments.
MapLight Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of MapLight Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Taewoong Co.Ltd
KQ:044490
|
Korea | ₩230.15 Billion |
|
Arad Ltd
TA:ARD
|
Israel | ILA211.30 Million |
|
Chengdu Shengbang Seals Co.Ltd.
SHE:301233
|
China | CN¥96.25 Million |
|
Qingdao Richmat Intelligence Technology Co. Ltd. A
SHE:301320
|
China | CN¥514.45 Million |
|
Malaysian Resources Corporation
KLSE:1651
|
Malaysia | RM4.74 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$2.39 Billion |
|
Perpetual Equity Investment Company Ltd
AU:PIC
|
Australia | AU$23.70 Million |
|
Nanjing OLO Home Furnishing
SHG:603326
|
China | CN¥813.52 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down MapLight Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see MapLight Therapeutics, Inc. Common Stock assets under control.
Liquidity & Leverage Metrics
MapLight Therapeutics, Inc. Common Stock Total Liabilities Ratios Explained
MapLight Therapeutics, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 16.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MapLight Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MapLight Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual total liabilities of MapLight Therapeutics, Inc. Common Stock from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $21.14 Million | -2.67% |
| 2024-12-31 | $21.72 Million | +7.92% |
| 2023-12-31 | $20.13 Million | +8.68% |
| 2022-12-31 | $18.52 Million | -- |
About MapLight Therapeutics, Inc. Common Stock
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irrit… Read more